The challenges of an HIV vaccine enterprise.
Publication
, Journal Article
Zinkernagel, RM
Published in: Science
February 27, 2004
Duke Scholars
Published In
Science
DOI
EISSN
1095-9203
Publication Date
February 27, 2004
Volume
303
Issue
5662
Start / End Page
1294 / 1297
Location
United States
Related Subject Headings
- Tuberculosis
- Public Health
- Immunity, Cellular
- Humans
- HIV Infections
- Global Health
- General Science & Technology
- BCG Vaccine
- AIDS Vaccines
Citation
APA
Chicago
ICMJE
MLA
NLM
Zinkernagel, R. M. (2004). The challenges of an HIV vaccine enterprise. Science, 303(5662), 1294–1297. https://doi.org/10.1126/science.303.5662.1294
Zinkernagel, Rolf M. “The challenges of an HIV vaccine enterprise.” Science 303, no. 5662 (February 27, 2004): 1294–97. https://doi.org/10.1126/science.303.5662.1294.
Zinkernagel RM. The challenges of an HIV vaccine enterprise. Science. 2004 Feb 27;303(5662):1294–7.
Zinkernagel, Rolf M. “The challenges of an HIV vaccine enterprise.” Science, vol. 303, no. 5662, Feb. 2004, pp. 1294–97. Pubmed, doi:10.1126/science.303.5662.1294.
Zinkernagel RM. The challenges of an HIV vaccine enterprise. Science. 2004 Feb 27;303(5662):1294–1297.
Published In
Science
DOI
EISSN
1095-9203
Publication Date
February 27, 2004
Volume
303
Issue
5662
Start / End Page
1294 / 1297
Location
United States
Related Subject Headings
- Tuberculosis
- Public Health
- Immunity, Cellular
- Humans
- HIV Infections
- Global Health
- General Science & Technology
- BCG Vaccine
- AIDS Vaccines